Toggle light / dark theme

Yuri Deigin — Defeating Aging

Andres de Tenyi.


Yuri Deigin, MBA is a serial biotech entrepreneur, longevity research evangelist and activist, and a cryonics advocate. He is an expert in drug development and venture investments in biotechnology and pharmaceuticals. He is the CEO at Youthereum Genetics and the Vice President at Science for Life Extension Research Support Foundation.
http://youthereum.ca/

Yuri has a track record of not only raising over $20 million for his previous ventures but also initiating and overseeing 4 clinical trials and several preclinical studies, including studies in transgenic mice.

At Youthereum Genetics, Yuri is currently leading a project dedicated to developing an epigenetic rejuvenation gene therapy, as intermittent epigenetic partial reprogramming demonstrated great experimental results in mice: it extended their lifespan by up to 50%.

His life goal is to do everything possible to minimize human suffering from various diseases, especially terminal age-related diseases such as cancer, Alzheimer’s, and cardiovascular disease and to help humanity eradicate them. As an activist, blogger, and speaker, he is conveying the magnitude of human suffering these diseases cause, as they take over 100,000 lives each day. As a biotech entrepreneur, Yuri is doing his modest part by putting together projects that could yield such therapies, splitting his time between Toronto and Moscow.

Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease

Takeaways * Scientists have made progress growing human liver in the lab. * The challenge has been to direct stems cells to grow into a mature, functioning adult organ. * This study shows that stem cells can be programmed, using genetic engineering, to grow from immature cells into mature tissue. * When a tiny lab-grown liver was transplanted into mice with liver disease, it extended the lives of the sick animals.* * *Imagine if researchers could program stem cells, which have the potential to grow into all cell types in the body, so that they could generate an entire human organ. This would allow scientists to manufacture tissues for testing drugs and reduce the demand for transplant organs by having new ones grown directly from a patient’s cells. I’m a researcher working in this new field – called synthetic biology – focused on creating new biological parts and redesigning existing biological systems. In a new paper, my colleagues and I showed progress in one of the key challenges with lab-grown organs – figuring out the genes necessary to produce the variety of mature cells needed to construct a functioning liver. Induced pluripotent stem cells, a subgroup of stem cells, are capable of producing cells that can build entire organs in the human body. But they can do this job only if they receive the right quantity of growth signals at the right time from their environment. If this happens, they eventually give rise to different cell types that can assemble and mature in the form of human organs and tissues. The tissues researchers generate from pluripotent stem cells can provide a unique source for personalized medicine from transplantation to novel drug discovery. But unfortunately, synthetic tissues from stem cells are not always suitable for transplant or drug testing because they contain unwanted cells from other tissues, or lack the tissue maturity and a complete network of blood vessels necessary for bringing oxygen and nutrients needed to nurture an organ. That is why having a framework to assess whether these lab-grown cells and tissues are doing their job, and how to make them more like human organs, is critical. Inspired by this challenge, I was determined to establish a synthetic biology method to read and write, or program, tissue development. I am trying to do this using the genetic language of stem cells, similar to what is used by nature to form human organs. Tissues and organs made by genetic designsI am a researcher specializing in synthetic biology and biological engineering at the Pittsburgh Liver Research Center and McGowan Institute for Regenerative Medicine, where the goals are to use engineering approaches to analyze and build novel biological systems and solve human health problems. My lab combines synthetic biology and regenerative medicine in a new field that strives to replace, regrow or repair diseased organs or tissues. I chose to focus on growing new human livers because this organ is vital for controlling most levels of chemicals – like proteins or sugar – in the blood. The liver also breaks down harmful chemicals and metabolizes many drugs in our body. But the liver tissue is also vulnerable and can be damaged and destroyed by many diseases, such as hepatitis or fatty liver disease. There is a shortage of donor organs, which limits liver transplantation. To make synthetic organs and tissues, scientists need to be able to control stem cells so that they can form into different types of cells, such as liver cells and blood vessel cells. The goal is to mature these stem cells into miniorgans, or organoids, containing blood vessels and the correct adult cell types that would be found in a natural organ. One way to orchestrate maturation of synthetic tissues is to determine the list of genes needed to induce a group of stem cells to grow, mature and evolve into a complete and functioning organ. To derive this list I worked with Patrick Cahan and Samira Kiani to first use computational analysis to identify genes involved in transforming a group of stem cells into a mature functioning liver. Then our team led by two of my students – Jeremy Velazquez and Ryan LeGraw – used genetic engineering to alter specific genes we had identified and used them to help build and mature human liver tissues from stem cells. The tissue is grown from a layer of genetically engineered stem cells in a petri dish. The function of genetic programs together with nutrients is to orchestrate formation of liver organoids over the course of 15 to 17 days. Liver in a dishI and my colleagues first compared the active genes in fetal liver organoids we had grown in the lab with those in adult human livers using a computational analysis to get a list of genes needed for driving fetal liver organoids to mature into adult organs. We then used genetic engineering to tweak genes – and the resulting proteins – that the stem cells needed to mature further toward an adult liver. In the course of about 17 days we generated tiny – several millimeters in width – but more mature liver tissues with a range of cells typically found in livers in the third trimester of human pregnancies. Like a mature human liver, these synthetic livers were able to store, synthesize and metabolize nutrients. Though our lab-grown livers were small, we are hopeful that we can scale them up in the future. While they share many similar features with adult livers, they aren’t perfect and our team still has work to do. For example, we still need to improve the capacity of the liver tissue to metabolize a variety of drugs. We also need to make it safer and more efficacious for eventual application in humans.[Deep knowledge, daily. Sign up for The Conversation’s newsletter.]Our study demonstrates the ability of these lab livers to mature and develop a functional network of blood vessels in just two and a half weeks. We believe this approach can pave the path for the manufacture of other organs with vasculature via genetic programming. The liver organoids provide several key features of an adult human liver such as production of key blood proteins and regulation of bile – a chemical important for digestion of food. When we implanted the lab-grown liver tissues into mice suffering from liver disease, it increased the life span. We named our organoids “designer organoids,” as they are generated via a genetic design. This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Mo Ebrahimkhani, University of Pittsburgh. Read more: * Brain organoids help neuroscientists understand brain development, but aren’t perfect matches for real brains * Why are scientists trying to manufacture organs in space?Mo Ebrahimkhani receives funding from National Institute of Health, University of Pittsburgh and Arizona Biomedical Research Council.

Why We Should Exercise Regularly — Ten Amazing Benefits

If you want to live long enough to see a reversal of aging and everlasting youth, exercise should be at the core of your routine.

Here I look at ten amazing benefits that exercise brings to your body and mind, so if you haven’t already got a regime on the go, hopefully this will convince you to start now.

Have an amazing day 🙂


In Why We Should Exercise Regularly, I show ten great areas that exercise benefits the body and mind.
If you want tp live longer and healthier, and slow down aging then regular exercise should be your first thought, especially if you have a sedentary job and have to spend long hours sat down.

Studies referenced.

Brain-on-a-chip: A history of development and future perspective

Brain on a chip for drug discovery.


Since the advent of organ-on-a-chip, many researchers have tried to mimic the physiology of human tissue on an engineered platform. In the case of brain tissue, structural connections and cell–cell interactions are important factors for brain function. The recent development of brain-on-a-chip is an effort to mimic those structural and functional aspects of brain tissue within a miniaturized engineered platform. From this perspective, we provide an overview of trace of brain-on-a-chip development, especially in terms of complexity and high-content/high-throughput screening capabilities, and future perspectives on more in vivo-like brain-on-a-chip development.

With the advent of an aging society, the disease incidence rate is increasing, and the cost of drug development and disease treatment is expanding exponentially.1,2 According to the World Health Organization (WHO), nearly one billion people in the world suffer from neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s diseases.3 Despite decades of research on neurodegenerative diseases by many biologists and pharmaceutical companies, the underlying mechanism of their onset and progression is still largely unknown. The resolution of these diseases has a long way to go, and such steps are limited due to the lack of a suitable in vitro model system for mechanism study and drug development. In particular, the complex tissue structures and cell–cell interactions of the in vivo system make it challenging to unravel the underlying mechanism of the diseases and to predict the efficacy of clinical medicine.

Cognitive performance of four-months-old ravens may parallel adult apes

Simone Pika and colleagues tested the cognitive skills of eight hand-raised ravens at four, eight, 12 and 16 months of age using a series of tests. The skills the authors investigated included spatial memory, object permanence—understanding that an object still exists when it is out of sight—understanding relative numbers and addition, and the ability to communicate with and learn from a human experimenter.

The authors found that the cognitive performance of ravens was similar from four to 16 months of age, suggesting that the speed at which the ravens’ cognitive skills develop is relatively rapid and near-to-complete by four months of age. At this age ravens become more and more independent from their parents and start to discover their ecological and social environments. Although varied between individuals, ravens generally performed best in tasks testing addition and understanding of relative numbers and worst in tasks testing spatial memory.

Chemists re-engineer a psychedelic to treat depression and addiction in rodents

“Researchers report today that they’ve created a nontoxic and nonhallucinogenic chemical cousin of ibogaine that combats depression and addictive behaviors in rodents. The work provides new hope that chemists may one day be able to create medicines for people that offer the purported therapeutic benefits of ibogaine and other psychoactive compounds without their side effects.”


Analog of ibogaine could hold hope for humans.

Genes for Regulating Stem Cell Aging Identified

Advanced, others might like.


The exact gene that caused stem cell aging has been identified.

Above – When mesenchymal stem/stromal cells (MSCs) age, the transcription factor GATA6 is increasingly produced in the cell to induce aging response. By transcription factor-based cellular reprogramming, aged MSCs are rejuvenated with a reduction in GATA6 effects on cellular aging. CREDIT AlphaMed Press

University of Wisconsin-Madison researchers found that the expression of GATA6, a protein that plays an important role in gut, lung and heart development, was repressed in the reprogrammed cells compared to the control cells. This repression led to an increase in the activity of a protein essential to embryonic development called sonic hedgehog (SHH) as well as the expression level of yet another protein, FOXP1, necessary for proper development of the brain, heart and lung. “Thus, we identified the GATA6/SHH/FOXP1 pathway as a key mechanism that regulates MSC aging and rejuvenation,” Dr. Li said.

French army gets ethical go-ahead for bionic soldiers

The French armed forces now have permission to develop “augmented soldiers” following a report from a military ethics committee.

The report, released to the public on Tuesday, considers medical treatments, prosthetics and implants that improve “physical, cognitive, perceptive and psychological capacities,” and could allow for location tracking or connectivity with weapons systems and other soldiers.

Dr Daniel Monti — CEO & Founding Director, Marcus Institute of Integrative Health — Jefferson Health

Exciting momentum!! — Home Depot Founder, Bernie Marcus (age 91), and the Adolph Coors Foundation (beer family), putting millions of $$$ into comprehensive integrative health and wellness — Good to see the trend!!


The Marcus Institute of Integrative Health was established in Philadelphia in 2017 by Thomas Jefferson University and Jefferson Health, and a multi-million $$$ grant from the Marcus Foundation (headed by it’s Chairman, Bernie Marcus, Co-Founder of The Home Depot) to expand the research, education and clinical care profile of Jefferson’s integrative medicine program, and to set the international standard of excellence in evidence-based, patient-centered integrative care.

The institute features a novel curriculum focusing on the clinical applications of integrative medicine with an emphasis on functional biochemistry, nutrient-based therapies, mind-body neuroscience, novel mechanisms of healing and emerging therapies.

Dr. Daniel Monti, MD, MBA is the Founding Director and Chief Executive Officer of the Marcus Institute of Integrative Health — Jefferson Health. He is also Professor and Founding Chair of the historic, first-ever Department of Integrative Medicine and Nutritional Sciences, Sidney Kimmel Medical College, Thomas Jefferson University.

Dr. Monti received his MD from The State University of New York at Buffalo School of Medicine. His Postdoctoral work was in the Research Scholars Program, Department of Psychiatry and Human Behavior, at Jefferson Medical College.